补充因子D是代谢相关脂肪肝疾病的药物标
1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Molecular immunology
|November 27, 2025
概括
补充因子D (CFD) 是代谢功能障碍相关脂肪肝疾病 (MAFLD) 的新型调解者. 用danicopan向CFD显示了通过减少肝脏脂肪和炎症来治疗MAFLD的治疗潜力.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 补充系统生物学 补充系统生物学
背景情况:
- 与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 是一种普遍的疾病,治疗选择有限.
- 补充因子D (CFD) 是补充激活中的关键酶,与代谢障碍有关.
- 对于MAFLD,CFD抑制的治疗潜力,特别是danicopan,在很大程度上是未被探索的.
研究的目的:
- 为了调查CFD在MAFLD病原体中的作用.
- 为了评估danicopan的疗效,一个CFD抑制剂,在治疗MAFLD.
- 阐明CFD参与和danicopan治疗效果背后的分子机制.
主要方法:
- 使用高脂肪饮食 (HFD) 诱导的MAFLD的小鼠模型.
- 在肝细胞中使用CRISPR-Cas9基因编辑用于CFD淘汰.
- 在药理上给肥胖小鼠用达尼科潘,并分析了MAFLD患者的肝/血清样本.
主要成果:
- 在MAFLD小鼠肝脏和人类患者血清中,CFD显著上调.
- 对CFD的基因切除减少了肝细胞中的脂质积累.
- 丹尼科潘治疗改善了葡萄糖耐受性,降低了肝酶 (ALT),并减轻了肥胖小鼠的肝肥胖症,而不会导致体重减轻.
结论:
- CFD被确定为一种新的调解者,有助于MAFLD.
- 丹尼科潘证明了MAFLD管理的治疗疗效和翻译潜力.
- 针对CFD途径是MAFLD治疗的一个有希望的策略.
相关概念视频
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
203
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
203
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
196
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
196
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
01:29Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
01:26Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K